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HIV/AIDS is a major public health burden, with an estimated 35.3 
million people infected globally.[1] Sub-Saharan Africa (SSA) bears 
the brunt of the pandemic, with 25 million HIV-positive people living 
in the region.[1] The advent of highly active antiretroviral therapy 
(HAART) has changed the natural history of HIV/AIDS, with a 
reported decline in mortality from 24.5 per 100 person-years in 1995 
to 8.9 per 100 in 1997,[2] and reportedly 2.1 per 100 in 2010.[3] Today 
HIV-positive patients in high-income countries are reported to have a 
life expectancy approaching that of the general population.[4] Despite 
evidence of the role of HAART in decreasing morbidity and mortality 
in HIV-positive patients, in resource-poor settings many people 
living with HIV do not have access to HAART or receive treatment 
late. Globally, only 9.7 million people were estimated to be receiving 
HAART in 2012.[5] Many HIV-positive people present with serious 
illnesses that may require intensive care unit (ICU) admission,[6] and a 
large proportion of these are unaware of their HIV status.[7] Data from 
high-income countries suggest that 7 - 12% of HIV-positive patients 
admitted to hospital are treated in the ICU.[8,9]
Historically, respiratory failure accounted for the majority of 
ICU admissions in the HIV-positive patient population, with an 
associated mortality of ~70%.[9,10] However, contemporary evidence 
from high-income countries suggests that ICU outcomes are similar 
to those of HIV-negative patients and that the indications for ICU are 
mostly not related to opportunistic infections (OIs).[10,11]
ICU utilisation and outcomes for HIV-positive patients in poorly 
resourced settings, where access to both intensive care and HAART is 
limited, have not been widely studied. With an increasing prevalence 
of HIV and an unchanging (and at times decreasing) number of 
available ICU beds, it is imperative to know the profile and outcome 
of HIV-positive patients requiring ICU admission in a resource-poor 
setting such as South Africa (SA).
Objective
To identify indications for ICU admission and determine factors 
associated with high ICU and hospital mortality in HIV-positive 
patients admitted to ICUs in a resource-limited setting. This will 
help in determining the appropriateness of offering ICU care to HIV-
positive patients and in the appropriate development of policies and 
planning for allocation of limited resources.
Methods
Study design and patient population
The study was a retrospective folder review conducted from 1 January 
2012 to 31 December 2012 in the medical and surgical ICUs at Groote 
Schuur Hospital (GSH), Cape Town, SA. GSH is a tertiary hospital 
affiliated to the University of Cape Town (UCT), and is an 867-bed 
institution with 16 general medicine and general surgery adult ICU 
beds (excluding the coronary care unit, the neurosurgical ICU and 
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the cardiothoracic ICUs). The GSH ICUs admit all patients deemed 
to require ICU care, irrespective of the need for ventilation. At the 
time of the study, GSH did not have a high-care unit. The GSH ICUs 
have no ICU admission criteria, admission being at the discretion of 
the treating or referring physician and the ICU physician on call at 
the time of ICU referral.
Patients were enrolled in the study if they were aged >18 years 
at the time of ICU admission, known to be HIV-positive, or newly 
diagnosed with HIV in the index admission.
Ward admission books and CLINICOM (a health information 
system including demographic and clinical patient data and providing 
a single electronic patient record that is accessible throughout 
the Western Cape Province of SA) records were interrogated for 
information on all the patients admitted to an ICU during the study 
period. Patient folders and laboratory records were examined for the 
results of HIV tests done during and prior to the index admission and 
for patient diagnoses during ICU admission.
Ethical approval
The study was carried out with the approval of the GSH and UCT 
Human Subjects Research Ethics Committee (ref. no. 044/2013). 
The need to obtain informed consent was waived, as this was a 
retrospective study and no identifying details would be included.
Case definition
Patients were coded as HIV-negative if they had had a negative HIV 
test 3 months prior to the index admission, and as untested if there 
was no documented HIV test result in the folder or no recorded HIV 
test in the National Health Laboratory Service electronic records. 
HIV infection was diagnosed by two positive antibody tests or one 
positive antibody test and a confirmatory Western blot test. No HIV 
testing was offered or done for the purpose of this study.
Data collection
A standardised form was used to collect demographic information, 
including age, sex and ethnic group. Details of length of ICU and 
hospital stay, use of mechanical ventilation and inotropic support 
were also recorded. The most recent CD4 count and HIV viral load, 
when available, were recorded. The Acute Physiology and Chronic 
Health Evaluation ΙΙ (APACHE ΙΙ) score was calculated using 
laboratory values obtained within 24 hours of ICU admission. Use 
of HAART before hospital admission was recorded. The presence of 
acute kidney injury (AKI) (as defined by Kidney Disease Improving 
Global Outcomes) on admission to the ICU and the use of renal 
replacement therapy (RRT) were documented.[12] Diagnoses at ICU 
admission were categorised by organ system and severity of sepsis.[13]
Statistical analysis
Data analysis was performed using SPSS version 20 (IBM, USA). 
Normality of data was tested using the Kolmogorov-Smirnov test. 
Normally distributed data are presented as means (standard deviation 
(SD)) or, where highly skewed, as medians (interquartile range 
(IQR)); discrete data are presented as numbers (percentages). The 
χ2 test or Fisher’s exact test was utilised to compare discrete data, as 
appropriate. In an attempt to identify factors associated with ICU and 
hospital mortality in HIV-positive individuals, HIV-positive patients 
who died in the ICU were compared with HIV-positive patients 
who were discharged alive from the ICU, and HIV-positive patients 
who died in hospital were compared with HIV-positive patients who 
were discharged alive. Analysis of variance with post-hoc Bonferroni 
correction was used to explore whether there were differences 
between the groups. Bivariate correlations were assessed using the 
Pearson r and Spearman rS coefficients, as appropriate. All statistical 
tests were two-tailed, with p<0.05 considered significant.
Results
From 1 January 2012 to 31 December 2012, 806 patients were 
admitted to the ICUs. Of these, 77 were HIV-positive, giving an 
incidence of 9.6 per 100 person-years. Two patients were aged 
<18 years and were excluded from the final analysis (Fig. 1). Two 
hundred and thirty-seven patients (29.4%) were HIV-uninfected 
or had tested HIV-negative during the 3 months prior to ICU 
admission. HIV status was unknown for 492 patients admitted to 
the ICUs (61.0%).
Patient demographic and clinical characteristics at  
ICU admission
A total of 75 patients were included in the analysis, with a mean (SD) 
age of 36.5 (9.6) years (Table 1). In keeping with the epidemiology of 
HIV infection in SSA, the majority of patients were female (64.0%). 
The CD4 count was available for 74 of the 75 patients. The median 
CD4 count was 232.5 (IQR 59 - 459) cells/µL. The HIV viral load was 
available for 27 patients, all of whom were receiving HAART at the 
time of ICU admission. Thirteen of the 27 patients had a detectable 
HIV viral load. The mean HIV viral load was 2 218 556.5 RNA 
copies/mL and the median HIV viral load was 20 146.5 (IQR 372.75 - 
25 898.75) RNA copies/mL. More than a third of the patients (37.3%) 
were newly diagnosed with HIV during the index hospital admission 
(Table 1).
Thirty-nine patients (52.0%) were not receiving HAART. The 
mean (SD) duration of HAART was 6.3 (17.5) months. No patients 
were started on antiretroviral therapy during their ICU stay.
ICU admission occurred after a median of 2 (IQR 1 - 6) days in the 
referring unit; 33 patients (44.0%) were admitted to the ICU within 
24 hours of arrival in hospital, 17 (22.7%) between 24 and 72 hours 
after arrival, and 25 (33.3%) >72 hours after arrival (Fig. 2). Thirty-
one patients (41.3%) were referred to the ICU from the general 
medical wards, 20.0% from casualty (medical emergency), 16.0% 
from the general surgical wards, 12.0% from the trauma ward and 
10.7% from maternity (Table 1). Approximately one-third (30.7%) 
of the patients were admitted to the ICU for respiratory illnesses. 
Fifteen of the patients with respiratory illness had community-
acquired pneumonia, four had pulmonary tuberculosis (initially 
referred to the ICU as community-acquired pneumonia) and the 
other four had Pneumocystis jirovecii pneumonia. The diagnosis of 































n=2, age <18 yr
Patients for analysis
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Fig. 1. Flow diagram showing patient enrolment. (ICU = intensive care unit.)
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patients diagnosed with P. jirovecii pneumonia had a new diagnosis 
of HIV infection. The other two patients with P. jirovecii pneumonia 
were known to be HIV-positive and were receiving HAART; their 
CD4 counts were <150 cells/µL, and both had a detectable HIV viral 
load. Ten patients had pulmonary tuberculosis and were receiving 
antituberculosis therapy before ICU admission. Nineteen patients 
had previous tuberculosis, which had been fully treated.
Patient clinical characteristics during the ICU stay
The majority of the patients (90.7%) required mechanical ventilation, 
and 50.7% required inotropic support. Fifty-five patients (73.3%) 
had AKI on admission to the ICU. RRT was offered to 24 patients 
(32.0%). Patients presented with a mean (SD) APACHE ΙΙ score of 
21.6 (8.4). The median numbers of days in the ICU and in hospital 
were 4 (IQR 2 - 8) and 16 (IQR 9 - 34), respectively.
ICU and hospital mortality
Nineteen patients (25.3%) died in the ICU, an additional 7 patients 
died in hospital after ICU discharge (9.3%), and 49 (65.3%) were 
discharged from hospital alive. Use of RRT was significantly 
associated with mortality in the ICU (odds ratio (OR) 2.2, 95% 
confidence interval (CI) 1.2 - 4.1; p=0.018), but not with hospital 
mortality (OR 1.9, 95% CI 1.0 - 3.6; p=0.056) (Table 2). The use of 
inotropes in the ICU was associated with both ICU (OR 2.3, 95% 
CI 1.6 - 3.4; p<0.001) and hospital mortality (OR 2.0, 95% CI 1.4 - 
3.2; p<0.001). An APACHE ΙΙ score of >13 at ICU admission was 
also significantly associated with increased ICU mortality (OR 1.4, 
95% CI 1.1 - 1.7; p=0.015), but not hospital mortality (OR 1.3, 95% 
CI 1.0 - 1.6; p=0.066). The number of days in the referring unit prior 
to ICU admission did not predict death in the ICU (p=0.075) or in 
hospital (p=0.191). Factors including CD4 count, use of HAART, 
mechanical ventilation, serum albumin and whether the patient was 
known to have or was newly diagnosed with HIV infection were not 
significantly associated with increased ICU or hospital mortality.
Discussion
The key findings of our study were: (i) that respiratory illnesses 
remain the major indication for ICU admission in HIV-positive 
patients; (ii) that there were ICU and hospital mortality rates of 25.3% 
and 34.7%, respectively, in a contemporary SA setting; and (iii) that 
factors associated with poor short-term outcomes in HIV-positive 
patients admitted to the ICU were the use of RRT, vasopressor 
support and an APACHE ΙΙ score >13. To our know ledge, this is the 
first study that has determined the outcomes of HIV-positive adults 
admitted to an SA ICU. These results have implications for resource 
allocation and management of HIV-positive patients requiring 
ICU care in resource-constrained settings. They suggest that sicker 
patients, as suggested by higher APACHE ΙΙ scores and the need 
for organ support such as RRT and inotropes in the setting of HIV 
infection, have worse outcomes. In resource-limited settings, ICU 
care may have to be withheld from HIV-positive patients who meet 
the above criteria. Furthermore, these results support the general 
criteria for ICU admission used in the SA public sector, which 
take into account the severity of the clinical presentation and the 
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Fig. 2. Time in the referring unit prior to intensive care unit admission.
Table 1. Patient characteristics (N=75)





Newly diagnosed HIV (%) 37.3
On HAART (%) 48.0
Duration of HAART (months), range 0 - 72
CD4 count (cells/µL), median (IQR) 232.5 (59 - 459)
Detectable HIV viral load (%) 18.7









Number of days in the referring unit, median 
(IQR)
2 (1 - 45)








APACHE ΙΙ score, mean (SD) 21.6 (8.4)
AKI on admission (%) 26.7
Mechanical ventilation (%) 90.7
RRT (%) 32.0




AKI and sepsis 17.3
Number of days in ICU, median (IQR) 4 (2 - 8)
Number of days in hospital, median (IQR) 16 (9 - 34)
SD = standard deviation; HAART = highly active antiretroviral therapy; IQR = 
interquartile range; ICU = intensive care unit; APACHE II = Acute Physiology and 
Chronic Health Evaluation ΙΙ; AKI = acute kidney injury; RRT = renal replacement 
therapy.
*Includes medical emergency (casualty) and trauma unit.
†Includes patients admitted with renal illness, malaria, gastrointestinal illness, emergency 
surgery and cardiac illness.
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Intensive care for HIV-positive patients was initially remarkable for 
high ICU and hospital mortality,[15,16] and in keeping with previous 
reports we found an ICU mortality rate of 25.3%.[10,17,18] Respiratory 
illnesses remain the leading diagnoses at ICU admission in HIV-
positive patients.[9,10] It has been reported that mechanical ventilation 
for respiratory illnesses is associated with poor ICU outcomes.[9,19-22] 
In this SA cohort, respiratory illnesses represented the most common 
indication for ICU admission, but were not associated with increased 
ICU and hospital mortality. We also did not find an association of 
mechanical ventilation with ICU and hospital mortality. In a study 
by Casalino et al.,[22] 45% of the patients with respiratory illnesses had 
P. jirovecii pneumonia. In the HAART era, the incidence of P. jirovecii 
pneumonia in HIV-positive patients admitted to ICUs has decreased 
to 3 - 9%.[10,11] Up to 50% of HIV-positive patients are unaware of their 
HIV status prior to ICU admission.[7,23-25] Compared with patients 
who are known to be HIV-positive prior to ICU admission, this 
patient group is characterised by pronounced immunosuppression 
and typically admitted with AIDS-related diagnoses such as 
P.  jirovecii pneumonia.[10,23,25-27] The frequency of newly diagnosed 
HIV-positive patients at ICU admission has remained relatively the 
same in the HAART era as in the pre-HAART era, but the frequency 
of OIs in the ICU has decreased.[7,9] Only 5.3% of our patients had 
P. jirovecii pneumonia. The diagnoses of P. jirovecii pneumonia was 
made during their ICU stay. P. jirovecii pneumonia, the need for 
mechanical ventilation in P. jirovecii pneumonia, development of 
a pneumothorax in P. jirovecii pneumonia and ICU admission for 
an AIDS-related diagnosis are widely thought to be related to high 
ICU and hospital mortality.[8,17,19,24,28] We do not have information 
on the number of HIV-positive patients who might have qualified 
for ICU care but were not referred to an ICU or were turned down 
for admission. This would help determine the reasons behind the 
denial of ICU care in this patient population and whether physician 
attitudes towards ICU care for HIV-positive patients have changed.
The severity of the acute event as marked by high APACHE ΙΙ 
scores,[9.28-30] the use of inotropes[27,31,32] and RRT[33] is reported to 
be associated with poor short-term outcomes. In this study, we 
found that a high APACHE ΙΙ score, use of inotropes and RRT were 
significantly associated with both ICU and hospital mortality in 
HIV-positive patients. Their presence in areas where resources are 
constrained could be used to determine whether ICU admission is 
warranted or intensive support should be initiated.
Between 24% and 50% of HIV-positive patients receive HAART 
prior to ICU admission.[8,10,23,26] Receipt of HAART prior to ICU 
admission has been associated with contradictory results in terms 
of association with short-term outcomes. Some authors have 
reported increased survival rates in patients on HAART prior to ICU 
admission, while others have reported that receipt of HAART did 
not predict short-term outcomes.[7,8,11,27] In our study, 48.0% of the 
patients were on HAART prior to ICU admission, but HAART prior 
to ICU admission did not predict ICU and hospital survival. Reports 
have shown that HIV viral load and CD4 count did not predict ICU 
and hospital survival.[11,27,28] Similarly, in our study we did not find any 
statistically significant association between detectable HIV viral load, 
low CD4 count and short-term outcomes in terms of either ICU or 
hospital mortality.
Up to 50% of HIV-positive persons have severe sepsis at ICU 
admission, or suffer from severe sepsis during their ICU stay.[32] 
Many infections responsible for sepsis in this patient population 
are nosocomial, followed by AIDS-related infections.[29] Ward stay 
prior to ICU admission is a risk factor for sepsis in HIV-positive 
patients. [32] Severe sepsis has been reported to be associated with 
poor ICU outcomes in HIV-positive patients.[32] In our study, 13.3% 
of the patients had a diagnosis of severe sepsis at ICU admission, and 
42.6% acquired severe sepsis during their ICU stay. We did not find 
an association between severe sepsis and death in this cohort.
The fact that 52.0% of the patients in our cohort were not receiving 
HAART, and 18.7% had a detectable HIV viral load while receiving 
HAART, suggests that improving ICU care plays a major role in 
the better outcomes of HIV-positive patients in the ICU. In our 
hospital, we have adopted lung-protective ventilation, surviving 
sepsis guidelines and appropriate glucose control in our ICUs.[34,35] 
There were very few case of P. jirovecii pneumonia, which may 
account for the apparent lack of association between respiratory 
illnesses, mechanical ventilation and death.
Study limitations
Our study has several important limitations: (i) it is a single-
centre study; (ii) it suffers from the limitations and biases of its 
Table 2. Patient outcomes according to specific variables
Death in 
ICU, n OR (95% CI) p-value
Death in 
hospital, n OR (95% CI) p-value 
Female (N=48) 15 1.2 (0.8 - 1.7) 0.403 16 0.9 (0.7 - 1.4) 0.746
Respiratory illnesses (N=23) 6 1.1 (0.5 - 2.3) 0.755 7 1.8 (0.4 - 1.7) 0.609
Severe sepsis (N=10) 3 1.1 (0.3 - 3.9) 0.880 6 2.8 (0.9 - 9.1) 0.071
AKI on admission (N=20) 7 1.7 (0.8 - 3.6) 0.163 8 1.3 (0.6 - 2.7) 0.558
Mechanical ventilation (N=68) 20 1.0 (0.9 - 1.2) 0.396 25 1.1 (1.0 - 1.2) 0.234
Renal replacement therapy (N=24) 11 2.2 (1.2 - 4.1) 0.018 12 1.9 (1.0 - 3.6) 0.056
Inotropic support (N=38) 18 2.3 (1.6 - 3.4) <0.001 20 2.0 (1.4 - 3.2) 0.001
APACHE ΙΙ >13 (N=57) 20 1.4 (1.1 - 1.7) 0.015 23 1.3 (1.0 - 1.6) 0.066
Newly diagnosed HIV (N=28) 10 1.4 (0.8 - 2.6) 0.251 11 1.2 (0.7 - 2.2) 0.516
Not on HAART (N=39) 13 1.3 (0.8 - 2.0) 0.284 16 1.3 (0.9 - 2.0) 0.228
Detectable HIV viral load (N=13) 4 1.3 (0.6 - 2.8) 0.580 5 1.3 (0.6 - 2.7) 0.586
CD4 count <200 cells/µL (N=35) 12 1.4 (0.9 - 2.3) 0.183 15 1.5 (0.9 - 2.3) 0.118
Time in the referring unit (hours) 0.075 0.191
<24 (N=33) 9 12
24 - 72 (N=17) 1 3
>72 (N=25) 9 14
ICU = intensive care unit; OR = odds ratio; CI = confidence interval; AKI = acute kidney injury; APACHE II = Acute Physiology and Chronic Health Evaluation ΙΙ;  
HAART = highly active antiretroviral therapy.
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retrospective nature; (iii) we were not able to find and document 
the microbiological causes of all the cases of community-acquired 
pneumonia, which could offer an opportunity for prophylaxis; and 
(iv) most importantly, 61.0% of our ICU population did not have an 
HIV test. Considering that our community has a high prevalence of 
HIV infection, this represents a missed opportunity for testing and 
potential treatment.
Conclusions
This study shows that critical care outcomes for HIV-positive patients 
at GSH are comparable to those in the developed world. As these are 
findings from a tertiary care unit, they are not representative of the 
rest of the country. The study highlights the fact that ICU outcomes 
for this patient population depend on the severity of the acute illness, 
irrespective of receipt of HAART and immune status. More research 
is needed that is representative of poorer provinces of SA and the rest 
of the African continent.
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